Introduction: Treatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (MDR) LTBI are lacking. This trial aims to evaluate the efficacy of the antibiotic levofloxacin in preventing the development of active TB among latently infected contacts of index patients with MDR-TB.
Methods And Analysis: A double-blind placebo-controlled parallel group randomised controlled trial will be conducted in 10 provinces of Vietnam. Household contacts living with patients with bacteriologically confirmed rifampicin-resistant or MDR-TB will be eligible for recruitment if they have a positive tuberculin skin test or are known to be immunosuppressed, and do not have active TB. Participants will be randomised to receive either levofloxacin or placebo tablets once per day for 6 months. Screening for incident TB will be performed at 6 months intervals. The primary study outcome is the incidence of bacteriologically confirmed TB within 30 months after randomisation. Analysis will be by intention to treat, using Poisson regression.
Ethics: Ethical approval from the University of Sydney Human Research Ethics Committee was obtained on 29 April 2015 (2014/929), and from the Vietnam Ministry of Health Institutional Review Board on 30 September 2015 (4040/QD-BYT).
Dissemination: Findings of the study will be published in peer-reviewed publications and conference presentations.
Trial Registration Number: ACTRN12616000215426.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955503 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2019-033945 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Latent Tuberculosis Infection Amongst Allogeneic Hematopoietic Stem Cell Transplant Recipients: The Impact of Routine Pretransplant Review by a Transplant Infectious Diseases Physician.
Transpl Infect Dis
December 2024
Department of Infectious Diseases and Immunology, Austin Health, Heidelberg, Australia.
Background: Identifying patients with latent tuberculosis infection (LTBI) is challenging. This is particularly true amongst immunocompromised hosts, in whom the diagnostic accuracy of available tests is limited. The authors evaluated the impact of routine pretransplant review by a transplant infectious diseases (TID) physician on LTBI screening in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients.
View Article and Find Full Text PDFReduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects.
BMC Microbiol
December 2024
Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renming East Road, Jinhua, Zhejiang, P. R. China.
Background: The gut microbiota plays a pivotal role in ulcerative colitis (UC) development. This study explores the impact of latent tuberculosis infection (LTBI) on the gut microbiota in UC and assesses changes during vedolizumab treatment, investigating prophylactic anti-tuberculosis therapy.
Results: This cohort study included adult patients with UC receiving vedolizumab treatment at Jinhua Hospital, Zhejiang University from April 2021 to December 2022.
The impact of the covid-19 pandemic on perceived diabetes care and regulation, with a focus on ethnic minorities: a mixed-methods study.
BMC Prim Care
December 2024
Health Campus The Hague/Department of Public Health and Primary Care, Leiden University Medical Center, The Hague, The Netherlands.
Background: This study aimed to explore the impact of the COVID-19 pandemic and resulting changes to diabetes care, especially concerning disease control, the use of (tele)consultation and lessons worth implementing to improve diabetes care, with a specific focus on ethnic minority groups.
Methods: A mixed-methods prospective cohort study among people with type 2 Diabetes Mellitus (T2DM) treated in primary care during the COVID-19 pandemic. A survey was sent regionally, including items related to teleconsultation and amount of contact with the healthcare professional.
Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.
Ann Surg Oncol
December 2024
Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Background: Immunochemotherapy is inevitably accompanied with treatment-related adverse events (TRAEs). However, TRAEs are typically assessed at a single time point, overlooking the complexity of TRAE trajectories over time. This study aimed to characterize TRAE trajectories during multi-cycle neoadjuvant immunochemotherapy (nICT) and identify potential prognostic factors for patients with esophageal squamous cell carcinoma (ESCC).
View Article and Find Full Text PDFText message-delivered cannabis use disorder treatment with young adults: A large randomized clinical trial.
J Subst Use Addict Treat
December 2024
College of Social Work, University of Kentucky, United States of America.
Background: Two scientific and clinical challenges for treating cannabis use disorder (CUD) are developing efficacious treatments with high likelihood of uptake and scalability, and testing the clinical mechanisms by which treatments work. Because young adults experience more CUD than other age groups, a need exists to test the efficacy and hypothesized causal pathways of novel treatments for CUD. Text-delivered treatments have the potential to reach young adults by increasing access and perceived privacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!